Michael F MacLean's Net Worth
$4.81 Million
Who is Michael F MacLean?
Michael F MacLean has an estimated net worth of $4.81 Million. This is based on reported shares across multiple companies, which include BIOGEN IDEC INC., Verve Therapeutics, Inc., Avidity Biosciences, Inc., and AKCEA THERAPEUTICS, INC..
SEC CIK
Michael F MacLean's CIK is 0001383731
Past Insider Trading and Trends
2023 was Michael F MacLean's most active year for acquiring shares with 5 total transactions. Michael F MacLean's most active month to acquire stocks was the month of January. 2008 was Michael F MacLean's most active year for disposing of shares, totalling 19 transactions. Michael F MacLean's most active month to dispose stocks was the month of March. 2008 saw Michael F MacLean paying a total of $89,568.75 for 34,265 shares, this is the most they've acquired in one year. In 2010 Michael F MacLean cashed out on 22,578 shares for a total of $1,300,771.52, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
BIOGEN IDEC INC. (BIIB) Snapshot price: $241.335
SVP, Chief Accounting Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -8.19% | -953.00 |
$56.53 | -$53,873.09 | 10.68K |
Oct 1
| |||
Form 4
| -45.06% | -9.54K |
$56.85 | -$542,456.51 | 11.63K |
Scheduled
|
Aug 2
| ||
Form 4/A
| -15.40% | -3.76K |
$60.00 | -$225,420.00 | 20.64K |
Scheduled
|
Mar 19
| ||
Form 4
| -16.74% | -4.08K |
$60.00 | -$245,100.00 | 20.31K |
Scheduled
|
Mar 19
| ||
Form 4
| +14.77% | 3.14K |
$55.29 | -$46,996.50 | 24.4K |
Feb 23 - Feb 24
| |||
Form 4
| -8.61% | -2.00K |
$55.21 | -$110,530.42 | 21.26K |
Feb 12
| |||
Form 4
| -5.63% | -1.39K |
$55.00 | -$76,395.00 | 23.26K |
Scheduled
|
Jan 19
| ||
Form 4
| +2.42% | 582 |
$42.13 | -$17,610.34 | 24.65K |
Nov 1
| |||
Form 4
| -3.81% | -953.00 |
$49.34 | -$47,021.02 | 24.07K |
Oct 1
| |||
Form 4
| +19.59% | 4.03K |
—
|
—
| 24.6K |
Feb 24
| |||
Form 4
| -8.89% | -2.01K |
$52.61 | -$105,588.27 | 20.57K |
Feb 12
| |||
Form 4
| +3.11% | 682 |
$42.55 | -$13,530.90 | 22.58K |
Nov 1
| |||
Form 4
| -8.55% | -2.05K |
$50.00 | -$102,350.00 | 21.89K |
Scheduled
|
Oct 6
| ||
Form 4
| -3.83% | -953.00 |
$49.59 | -$47,259.27 | 23.94K |
Oct 1
| |||
Form 4
|
—
|
0
|
$60.27 | -$46,875.00 | 24.89K |
Scheduled
|
Jul 31
| ||
Form 4
| -2.67% | -682.00 |
$70.00 | -$47,740.00 | 24.89K |
Scheduled
|
Jul 22
| ||
Form 4
| -7.97% | -2.21K |
$64.37 | -$142,507.58 | 25.58K |
Scheduled
|
Apr 8
| ||
Form 4
| +35.37% | 7.14K |
$60.56 | -$67,827.20 | 27.33K |
Feb 12
| |||
Form 4
| +3.54% | 682 |
$72.87 | -$23,172.66 | 19.95K |
Nov 1
| |||
Form 4
| +87.93% | 9K |
—
|
—
| 19.23K |
Oct 1
| |||
Form 4
|
∞
| 10K |
—
|
—
| 10K |
Feb 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Verve Therapeutics, Inc. (VERV) Snapshot price: $10.995
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Avidity Biosciences, Inc. (RNA) Snapshot price: $12.2
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +87.93% | 38.77K |
$39.13 | -$439,344.90 | 82.86K |
Scheduled
|
Jun 17 - Jun 18
| ||
Form 4
|
—
|
0
|
$22.27 | -$2,803,700.55 | 44.09K |
Scheduled
|
Jun 12
| ||
Form 4
|
—
|
0
|
$18.55 | -$1,459,545.00 | 44.09K |
May 14
| |||
Form 4
|
—
|
0
|
$16.67 | -$627,960.00 | 44.09K |
Scheduled
|
Mar 13
| ||
Form 4
| +89.98% | 20.88K |
$10.13 | -$16,370.08 | 44.09K |
Scheduled
|
Jan 20 - Jan 22
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 11
| |||
Form 4
| +551.91% | 18.5K |
—
|
—
| 21.85K |
Jan 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AKCEA THERAPEUTICS, INC. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +140.00% | 28K |
—
|
—
| 48K |
Jan 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
∞
| 20K |
—
|
—
| 20K |
Sep 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||